Novo Nordisk Aktie - NOV

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

64,04

Gebot

63,95

Fragen

64,12

Volumen

177.949

63,23 Tagesbereich 65,84

9,6779 52-Wochen-Bereich 139,88

Marktkapitalisierung

287,925B

Handelsende

65,20

Handelsbeginn

65,59

Letzte Trade

64.13

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

241.748

Ausgegebene Aktien

4.496.011.436

Dividendenrendite

132.78%

Kurs-Gewinn-Verhältnis

3,29

Gewinn pro Aktie (EPS)

22,46

Erlöse

290,4B

Nettogewinn

100,99B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.novonordisk.com

Hauptsitz

Bagsvaerd, Dnk

Gegründet

Novo Nordisk is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker NOV. The last closing price for Novo Nordisk was 65,20 €. Over the last year, Novo Nordisk shares have traded in a share price range of 9,6779 € to 139,88 €.

Novo Nordisk currently has 4.496.011.436 shares in issue. The market capitalisation of Novo Nordisk is 293,14 € billion. Novo Nordisk has a price to earnings ratio (PE ratio) of 3.29.

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according...

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 Subcutaneous amycretin phase 1b/2a data on...

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development Bagsværd, Denmark, 12 June 2025 –...

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and...

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced...

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced...

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases...

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 9 May 2025 — This company...

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-5.26	-7.59018759019	69.3	71.53	63.23	212245	66.64876662	DE
4	3.39	5.58944765045	60.65	71.53	58.4	193223	65.37274936	DE
12	-0.46	-0.713178294574	64.5	71.53	52.51	241748	60.95179221	DE
26	-35.96	-35.96	100	100.1	9.6778999	218048	69.8485499	DE
52	-68.46	-51.6679245283	132.5	139.88	9.6778999	139198	80.62707485	DE
156	-27.66	-30.1635768811	91.7	139.88	9.6778999	107054	87.67199258	DE
260	-27.66	-30.1635768811	91.7	139.88	9.6778999	107054	87.67199258	DE

NOV - Frequently Asked Questions (FAQ)

What is the current Novo Nordisk share price?

The current share price of Novo Nordisk is 64,04 €

How many Novo Nordisk shares are in issue?

Novo Nordisk has 4.496.011.436 shares in issue

What is the market cap of Novo Nordisk?

The market capitalisation of Novo Nordisk is EUR 293,14B

What is the 1 year trading range for Novo Nordisk share price?

Novo Nordisk has traded in the range of 9,6779 € to 139,88 € during the past year

What is the PE ratio of Novo Nordisk?

The price to earnings ratio of Novo Nordisk is 3,29

What is the cash to sales ratio of Novo Nordisk?

The cash to sales ratio of Novo Nordisk is 1,14

What is the reporting currency for Novo Nordisk?

Novo Nordisk reports financial results in DKK

What is the latest annual turnover for Novo Nordisk?

The latest annual turnover of Novo Nordisk is DKK 290,4B

What is the latest annual profit for Novo Nordisk?

The latest annual profit of Novo Nordisk is DKK 100,99B

What is the registered address of Novo Nordisk?

The registered address for Novo Nordisk is NOVO ALLE, BAGSVAERD, DK-2880

What is the Novo Nordisk website address?

The website address for Novo Nordisk is www.novonordisk.com

Which industry sector does Novo Nordisk operate in?

Novo Nordisk operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WS90Provaris Energy Ltd	0,011 € (61,76%)	2,66M
XABNetlist Inc Dl 001	0,84 € (37,70%)	90,68k
47FLQWD Technologies Corp	2,72 € (36,00%)	16,17k
EJ7Energy Resources of Australia	0,002 € (33,33%)	1M
E3O1Nexoptic Technology Corp	0,0105 € (31,25%)	13,52k
PHPNGalectin Therapeutics Inc	1,82 € (-36,36%)	12,69k
1SSNextech3d Ai Corp	0,0118 € (-32,95%)	281
EUSKore Mining Ltd	0,015 € (-28,57%)	9k
PU11Social Chain AG	0,0145 € (-27,50%)	10
M13VERSES AI Inc	3,30 € (-27,02%)	34,68k
E3BEutelsat Communications	3,59 € (26,63%)	5,86M
WS90Provaris Energy Ltd	0,011 € (61,76%)	2,66M
D7GNel ASA	0,2076 € (1,47%)	2,18M
3WUFreeman Gold Corp	0,0975 € (5,41%)	2,15M
Z620Trillion Energy International Inc	0,0395 € (1,80%)	2,05M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novo Nordisk (NOV)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novo Nordisk

NOV Neueste Nachrichten

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

NOV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novo Nordisk (NOV) Börsenkurse

Novo Nordisk (NOV)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novo Nordisk

NOV Neueste Nachrichten

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

NOV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen